DLBCL
Clinical trials for DLBCL explained in plain language.
Never miss a new study
Get alerted when new DLBCL trials appear
Sign up with your email to follow new studies for DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a targeted pill boost lymphoma cure rates?
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug acalabrutinib to standard chemotherapy and rituximab can improve cure rates for people with untreated diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. About 132 adults with aggressive B-cell lymphom…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New Antibody-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination o…
Matched conditions: DLBCL
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New CAR-T therapy targets BAFF-R to fight resistant lymphoma
Disease control Recruiting nowThis early-phase trial tests a new treatment called BAFF-R CAR-T for people with B-cell lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells carrying a protein called BAFF-…
Matched conditions: DLBCL
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells take aim at stubborn lymphoma
Disease control Recruiting nowThis early-phase trial tests whether a personalized immune cell therapy called anti-EBV TCR-T cells is safe for people with relapsed or refractory EBV-positive lymphoma who have a specific genetic marker (HLA-A11:01). The treatment involves taking a patient's own T cells, enginee…
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Smart scans could spare lymphoma patients from extra chemo
Knowledge-focused Recruiting nowThis study tests whether PET scans and blood tests for tumor DNA can help doctors adjust chemotherapy for people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 participants will receive standard R-CHOP treatment, and their response will be monitored with imaging…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New study aims to unlock better care for frail lymphoma patients
Knowledge-focused Recruiting nowThis study is collecting information and samples from 800 people with large B-cell lymphoma who are either too frail for standard treatment or have not responded to initial therapy. The goal is to understand how these patients are managed and what outcomes they have, which could …
Matched conditions: DLBCL
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC